Author

Héctor Lucas Luciardi

Observed names: H Luciardi, H. Luciardi, HECTOR LUCAS LUCIARDI, Hector L Luciardi, Hector L. Luciardi, Hector Lucas Luciardi, Hector Luciardi, Héctor Lucas Luciardi, Héctor L Luciardi, Héctor L. Luciardi, Héctor Lucas-Luciardi, Héctor Luciardi, LUCIARDI, HECTOR LUCAS, Luciardi, H.L., Luciardi, Héctor Lucas

Observed institutions: National University of Tucumán, Universidad de Buenos Aires

OpenAlex ID: A5111903512

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

2017 · Sonia S Anand, Jackie Bosch, et al. · The Lancet · 883

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

2017 · Stuart J Connolly, John W Eikelboom, et al. · The Lancet · 754

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

2019 · Kausik K Ray, Helen M Colhoun, et al. · The Lancet Diabetes & Endocrinology · 315

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

2021 · Gregory G. Schwartz, Gregory G. Schwartz, et al. · Journal of the American College of Cardiology · 148

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

2022 · Emil Hagström, P. Gabriel Steg, et al. · Circulation · 118

The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?

2004 · Raul Altman, Héctor L Luciardi, et al. · Thrombosis Journal · 115

Efficacy Assessment of Meloxicam, a Preferential Cyclooxygenase-2 Inhibitor, in Acute Coronary Syndromes Without ST-Segment Elevation

2002 · Raul Altman, Hector L. Luciardi, et al. · Circulation · 109

Diagnosis, Management, and Treatment of Chronic Chagas' Heart Disease in Areas Where Trypanosoma cruzi Infection Is Not Endemic

2007 · Joaquim Gascón, Pedro Albajar, et al. · Revista Española de Cardiología (English Edition) · 106

Diagnóstico, manejo y tratamiento de la cardiopatía chagásica crónica en áreas donde la infección por Trypanosoma cruzi no es endémica

2007 · Joaquim Gascón, Pedro Albajar, et al. · Revista Española de Cardiología · 102

Effects of blood pressure and lipid lowering on cognition

2019 · Jackie Bosch, Martin O'Donnell, et al. · Neurology · 85

Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry

2019 · Shinya Goto, Pantep Angchaisuksiri, et al. · Journal of the American Heart Association · 53

RBD-specific polyclonal F(ab´)2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial

2021 · Gustavo Lopardo, Waldo H. Belloso, et al. · EClinicalMedicine · 47

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

2021 · Gregory G. Schwartz, Michael Szarek, et al. · Diabetes Care · 40

Estado protrombótico en estadios tempranos de la enfermedad de Chagas crónica

2003 · Ramón N. Herrera, Elba Díaz, et al. · Revista Española de Cardiología · 33

Diagnóstico, manejo y tratamiento de la cardiopatía chagásica crónica en áreas donde la infección por Trypanosoma cruzi no es endémica

2008 · Joaquim Gascón, Pedro Albajar, et al. · Enfermedades Infecciosas y Microbiología Clínica · 29

Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES

2025 · P. Gabriel Steg, Michael Szarek, et al. · Circulation · 26

Diagnostic role of new Doppler index in assessment of renal artery stenosis

2006 · Sergio Chain, Hector Luciardi, et al. · Cardiovascular Ultrasound · 26

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

2024 · Shaun G Goodman, Philippe Gabriel Steg, et al. · European Heart Journal - Cardiovascular Pharmacotherapy · 25

Stroke prevention in patients from Latin American countries with non‐valvular atrial fibrillation: Insights from the GARFIELD‐AF registry

2019 · Carlos Jerjes‐Sanchez, Ramon Corbalan, et al. · Clinical Cardiology · 25

Inflammatory and Prothrombotic Activation With Conserved Endothelial Function in Patients With Chronic, Asymptomatic Chagas Disease

2010 · Ramón N. Herrera, Elba I. Díaz de Amaya, et al. · Clinical and Applied Thrombosis/Hemostasis · 25

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry

2018 · Jitendra PS. Sawhney, Veerappa A. Kothiwale, et al. · Indian Heart Journal · 22

[Prevalence of thyroid dysfunction in patients with type 2 diabetes mellitus].

2017 · Mirta Centeno Maxzud, Luciana Gómez Rasjido, et al. · PubMed · 22

Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD‐AF and treated with vitamin K antagonists

2016 · David A. Fitzmaurice, Gabriele Accetta, et al. · British Journal of Haematology · 17

[Prothrombotic state in early stages of chronic Chagas' disease. Its association with thrombotic risk factors].

2006 · Ramón N Herrera, Elba Díaz, et al. · PubMed · 16

GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide

2022 · Sylvia Haas, John A. Camm, et al. · Clinical Research in Cardiology · 12

Works count: 74

Citation count: 3,190

H-index: 22

I10-index: 25